NAMSA Acquires Medvance Ltd.

NAMSA, the world’s leading medical research organization, has acquired Medvance Ltd., a clinical research and resourcing company based in Yorkshire, England.

The addition of Medvance expands NAMSA’s MRO approach to consulting and testing, adding support across the United Kingdom and continental Europe to NAMSA’s global footprint in the United States, Germany, France and China, the company claims. NAMSA supports clients through all product development phases, from regulatory knowledge through non-clinical and clinical research as well as postmarket products and services. By combining the two companies, NAMSA has experts in nearly every therapeutic area to accelerate product development, market approval and extend market acceptance in all major markets around the globe, executives noted.

“NAMSA is pleased to now be able to offer Medvance’s regulatory, clinical and resourcing services along with our expertise in R&D, biocompatibility and clinical research,” said John Gorski, NAMSA’s president/CEO. “Having experts across even more geographies will help clients deliver their products more effectively to the physicians and patients around the world who need them most.”

Medvance will hereafter be referred to as NAMSA Medvance. Janette Benaddi, Medvance CEO, will remain part of the new NAMSA Medvance in a key executive role.

“Medvance clients will benefit from NAMSA’s deep expertise in biostatistics as well as their material scientists and biocompatibility experts,” Benaddi said. “In addition, NAMSA’s strength and relationships offer clients more insight into the U.S., Japan and China.”

NAMSA is a global medical research, testing and consulting services firm that evaluates safety and efficacy of medical devices, in-vitro diagnostics and combination products.